Moxonidine

Overview

Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I 1 -R) agonist. Moxonidine activates imidazoline I 1 receptors and α 2 adrenoceptors , affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Depression | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Imidazoline Receptor | Products > Signaling Pathways > Adrenergic Receptor | Products > Signaling Pathways > LDLR

Product Information

• Catalog No.: HY-B0374
• CAS No.: 75438-57-2
• Molecular Formula: C9H12ClN5O
• Molecular Weight: 241.68
• Purity: 99.72%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution
• Availability: In-stock

Source

Original product source